---
title: "Global Synthetic Biology Market Research Report 2025"
datePublished: Mon Oct 06 2025 15:42:23 GMT+0000 (Coordinated Universal Time)
cuid: cmgfauld2000002l5booh7lmg
slug: global-synthetic-biology-market-research-report-2025-1

---

# Global Synthetic Biology Market Research Report 2025

<p>
</p><p><strong>MARKET INSIGHTS</strong></p><p>
</p><div><b>Download FREE Sample of this Report @ 
            <a href="https://www.24chemicalresearch.com/download-sample/100708/global-synthetic-biology-market">
            https://www.24chemicalresearch.com/download-sample/100708/global-synthetic-biology-market</a></b></div><br><p>Global synthetic biology market size was valued at USD 13.4 billion in 2024. The market is projected to grow from USD 16.2 billion in 2025 to USD 45.8 billion by 2032, exhibiting a CAGR of 23.5% during the forecast period.</p><p>
</p><p>Synthetic biology represents a multidisciplinary field combining biology and engineering to design and construct new biological systems or redesign existing ones. This technology enables the programming of biological components such as DNA sequences, proteins, and metabolic pathways for applications ranging from medicine to industrial biotechnology. Core technologies include gene synthesis, genome editing tools like CRISPR, DNA assembly methods, and computational modeling platforms.</p><p>
</p><p>While North America currently dominates market share, Asia-Pacific is emerging as the fastest-growing region due to increasing R&amp;D investments and government initiatives. The market expansion is driven by rising demand for synthetic genes, bio-based products, and advancements in genome editing. However, ethical concerns and regulatory challenges present potential hurdles to growth. Recent developments include Ginkgo Bioworks' 2024 acquisition of Zymergen, creating one of the largest synthetic biology platforms with expanded capabilities in bioindustrial applications.</p><p>

</p><p>
<strong>Global Synthetic Biology Market Research Report 2025-2032</strong></p><p>
<strong>MARKET DYNAMICS</strong></p><p>
<strong>MARKET DRIVERS</strong></p><p>
</p><p style="text-align:center"><strong>Expansion of CRISPR Technology Accelerating Synthetic Biology Adoption</strong></p><p>
</p><p>The accelerated adoption of CRISPR-based genome editing tools continues to propel synthetic biology innovation. Since its discovery, CRISPR-Cas9 systems have become fundamental in genetic engineering, with applications spanning therapeutics, agriculture, and industrial biotechnology. The technology's precision and cost-effectiveness compared to traditional methods has led to widespread implementation - the gene editing market is projected to maintain a compound annual growth rate exceeding 20% through 2032. Recent breakthroughs in base and prime editing offer even greater precision, reducing off-target effects that previously limited clinical applications. Therapeutic areas like rare genetic disorders and oncology particularly benefit from these advancements, with over 500 active CRISPR clinical trials underway globally as of 2024.</p><p>
</p><p style="text-align:center"><strong>Bio-based Manufacturing Revolution Driving Industrial Applications</strong></p><p>
</p><p>Synthetic biology enables sustainable alternatives to petroleum-derived products through engineered biological systems, gaining traction amid environmental regulations and consumer demand. The industrial segment now represents over 30% of synthetic biology applications, producing bio-based chemicals, materials, and biofuels. Major corporations across consumer goods, textiles, and packaging are transitioning to bio-manufactured ingredients to meet sustainability commitments. Advancements in strain engineering and fermentation technologies have improved yield, scalability, and cost-efficiency of these biological production platforms. By 2030, bio-based chemicals could account for nearly 25% of the chemical market, representing a paradigm shift in manufacturing.</p><p>
</p><p style="text-align:center"><strong>Convergence with AI and Automation Streamlining Design-Build-Test Cycles</strong></p><p>
</p><p>The integration of artificial intelligence with synthetic biology has dramatically accelerated the design of genetic constructs and metabolic pathways. Machine learning algorithms analyze vast biological datasets to predict optimal DNA sequences, while robotic automation enables high-throughput testing of engineered organisms. Leading companies have reduced development timelines from years to months through these technologies, with some laboratories executing over 50,000 genetic experiments weekly. Cloud-based biodesign platforms now allow researchers worldwide to collaborate and simulate biological systems before physical construction, further democratizing access to synthetic biology tools.</p><p>
<strong>MARKET RESTRAINTS</strong></p><p>
</p><p style="text-align:center"><strong>Regulatory Ambiguity Limiting Commercialization Potential</strong></p><p>
</p><p>While synthetic biology innovations progress rapidly, regulatory frameworks struggle to keep pace, creating uncertainty for product development. Genetically modified organisms (GMOs) face particularly complex approval processes that vary significantly by jurisdiction. The European Union's precautionary approach contrasts with more flexible U.S. regulations, complicating global market strategies. Regulatory delays add substantial costs - bringing a single engineered organism through approval can exceed $50 million. Recent controversies around gene-edited crops demonstrate how public perception continues to influence policy, potentially restricting applications despite scientific consensus on safety.</p><p>
</p><p style="text-align:center"><strong>Biosafety Concerns Impacting Public and Investor Confidence</strong></p><p>
</p><p>Potential risks associated with synthetic organisms, including unintended environmental impacts and dual-use applications, remain key concerns. High-profile incidents like COVID-19 have heightened sensitivity to biological risks, despite synthetic biology's potential benefits. Stringent containment requirements increase operational costs for biofoundries and manufacturing facilities. Some investors remain cautious about companies working with engineered pathogens or other higher-risk organisms due to liability concerns. The industry continues developing safer chassis organisms and kill-switch mechanisms to address these concerns, but public perception challenges persist.</p><p>
</p><p style="text-align:center"><strong>Intellectual Property Complexity Creating Legal Uncertainties</strong></p><p>
</p><p>The patent landscape for synthetic biology tools has become increasingly complex, with overlapping claims and litigation risks slowing innovation. CRISPR technology patents alone have spawned years of disputes between major institutions. Small companies face particular challenges navigating IP waters, as licensing costs for foundational technologies can consume significant capital. Some researchers advocate for open-source approaches to overcome these barriers, but questions remain about sustainable business models. Recent court decisions have provided some clarification, but IP uncertainties continue affecting investment decisions.</p><p>
<strong>MARKET OPPORTUNITIES</strong></p><p>
</p><p style="text-align:center"><strong>Climate Change Mitigation Driving Bio-innovation Investments</strong></p><p>
</p><p>Synthetic biology offers promising solutions for carbon sequestration and sustainable agriculture as climate concerns intensify. Engineered microbes that convert CO2 into valuable chemicals and crops with enhanced carbon capture capabilities are attracting significant funding. Governments worldwide are allocating billions to bio-based climate solutions through initiatives similar to the U.S. Bioeconomy Executive Order. The emerging carbon capture biotechnology sector could generate over $100 billion annually by 2030 if current pilot projects demonstrate commercial viability. Companies developing drought-resistant crops and soil-enhancing microbes also stand to benefit from growing climate adaptation needs.</p><p>
</p><p style="text-align:center"><strong>Pharmaceutical Innovation Creating New Therapeutic Paradigms</strong></p><p>
</p><p>The success of mRNA vaccines has reinvigorated interest in synthetic biology applications for drug development. Cell and gene therapies, RNA-based medicines, and microbiome modulators represent the next frontier. Synthetic biology enables rapid vaccine development against emerging pathogensâsome COVID-era platforms demonstrated the ability to develop candidates in under 100 days. With over 3,000 biotech companies pursuing advanced therapies, demand for DNA synthesis, gene editing tools, and synthetic biology services continues rising. The push for more effective oncology treatments particularly drives innovation, as engineered immune cells and targeted therapies demonstrate remarkable clinical results.</p><p>
</p><p style="text-align:center"><strong>Decentralization of Biomanufacturing Expanding Market Access</strong></p><p>
</p><p>Advancements in miniaturized bioreactors and distributed manufacturing models are making synthetic biology more accessible globally. Portable biofoundries allow local production of vaccines, diagnostics, and therapies without complex supply chainsâcritical for resource-limited settings. This decentralization aligns with pandemic preparedness goals while opening new markets. Emerging economies are investing in domestic synthetic biology capabilities, with several Asian and African nations establishing national bioeconomy strategies. Distributed manufacturing could transform how biologics are produced, potentially reducing costs and improving access to essential medicines worldwide.</p><p>
<strong>MARKET CHALLENGES</strong></p><p>
</p><p style="text-align:center"><strong>Scaling Bottlenecks Constraining Commercial Viability</strong></p><p>
</p><p>While laboratory successes frequently demonstrate proof-of-concept, translating synthetic biology innovations to industrial scale remains a persistent challenge. Fermentation processes that work in small bioreactors often encounter unexpected complications when scaled. Yield variability, contamination risks, and byproduct accumulation can render promising technologies economically unviable at production volumes. Some companies report losing 50-70% of projected yields during scale-up attempts. Solving these challenges requires interdisciplinary expertise spanning biology, engineering, and data scienceâa skills combination that remains scarce in the workforce.</p><p>
</p><p style="text-align:center"><strong>Talent Shortage Restricting Industry Growth</strong></p><p>
</p><p>The synthetic biology sector faces a severe workforce shortage, with demand for skilled professionals outpacing supply. Specialized roles like automation engineers and computational biologists are particularly difficult to fill, with some companies reporting hundreds of unfilled positions. Academic programs have struggled to keep pace with industry needs, creating a skills gap. Retraining programs and alternative education pathways are emerging, but significant investment in STEM education is required to support long-term growth. The competition for top talent has also driven up salaries, increasing operational costs across the sector.</p><p>
</p><p style="text-align:center"><strong>Infrastructure Limitations Impeding Distributed Models</strong></p><p>
</p><p>While decentralized biomanufacturing holds promise, significant infrastructure challenges must be addressed. Many regions lack the cold chain logistics, quality control systems, and regulatory oversight required for reliable production. Power reliability, clean water access, and waste management systems vary widely across potential manufacturing locations. Successful decentralization will require substantial investments in both physical infrastructure and digital monitoring systems to ensure product quality and safety standards are maintained across distributed networks.</p><p>


<strong>Segment Analysis:</strong></p><p>
<strong>By Type</strong></p><p>
</p><p><strong>Gene Synthesis Holds Largest Share Due to Expanding Applications in CRISPR and Protein Engineering</strong></p><p>
</p><p>The market is segmented based on type into:</p><p>
</p><p>Gene synthesis</p><p>Genome engineering</p><p>Next-generation sequencing</p><p>Microfluidics</p><p>Nanotechnology</p><p>
<strong>By Application</strong></p><p>
</p><p><strong>Medical Applications Drive Market Growth Fueled by Therapeutics and Diagnostics Development</strong></p><p>
</p><p>The market is segmented based on application into:</p><p>
</p><p>Medical applications</p><p>Industrial applications</p><p>Food and agriculture</p><p>Environmental applications</p><p>
<strong>By End User</strong></p><p>
</p><p><strong>Pharmaceutical &amp; Biotech Companies Lead Demand for Drug Development Platforms</strong></p><p>
</p><p>The market is segmented based on end user into:</p><p>
</p><p>Pharmaceutical &amp; biotechnology companies</p><p>Academic &amp; research institutions</p><p>Contract research organizations</p><p>Diagnostic laboratories</p><p>
<strong>By Technology</strong></p><p>
</p><p><strong>CRISPR-Cas Systems Dominate Due to Precision Editing Capabilities Across Industries</strong></p><p>
</p><p>The market is segmented based on technology into:</p><p>
</p><p>CRISPR-Cas systems</p><p>Synthetic DNA/RNA</p><p>Bioinformatics tools</p><p>Directed evolution</p><p>
<strong>Global Synthetic Biology Market Overview</strong></p><p>
</p><p>The global synthetic biology market continues to demonstrate robust growth, driven by increasing applications across healthcare, agriculture, and industrial biotechnology sectors. <strong>The market was valued at approximately $10.7 billion in 2024</strong> and is projected to expand at a compound annual growth rate (CAGR) of <strong>24.8%</strong> from 2025 to 2032, potentially reaching <strong>$60 billion by 2032</strong>. This remarkable growth trajectory stems from advancements in gene editing technologies, decreasing DNA sequencing costs, and rising investments in bio-manufacturing.</p><p>
<strong>COMPETITIVE LANDSCAPE</strong></p><p>
<strong>Key Industry Players</strong></p><p>
</p><p style="text-align:center"><strong>Innovation and Strategic Expansion Define Market Leadership</strong></p><p>
</p><p>The synthetic biology market features a dynamic competitive environment with established pharmaceutical giants competing alongside specialized biotech firms. <strong>Ginkgo Bioworks</strong> has emerged as a market leader through its revolutionary cell programming platform, securing multiple partnerships with Fortune 500 companies. Meanwhile, <strong>Thermo Fisher Scientific</strong> maintains dominance through its comprehensive suite of synthetic biology tools serving research and industrial applications.</p><p>
</p><p><strong>Twist Bioscience</strong> continues gaining market share with its high-throughput DNA synthesis capabilities, while <strong>CRISPR Therapeutics</strong> leads in therapeutic applications through groundbreaking gene editing solutions. These companies are actively expanding their capabilities through both organic R&amp;D and strategic acquisitions. For instance, <strong>Merck KGaA's</strong> 2023 acquisition of a synthetic biology AI platform strengthened its position in computational biodesign.</p><p>
</p><p>The competitive intensity is further heightened by specialized players like <strong>Zymergen</strong> and <strong>Synthace</strong>, who are redefining industrial biotechnology applications. These innovators are driving down production costs for bio-based materials, creating new market opportunities beyond traditional pharmaceutical applications.</p><p>
<strong>List of Key Synthetic Biology Companies</strong></p><p>
</p><p>
</p><p>While North American firms currently dominate revenue share, Asian manufacturers like <strong>BGI Group</strong> are rapidly expanding capabilities in genome engineering and synthetic biology services. The competitive landscape continues evolving as startups focused on AI-driven biodesign and automated biofoundries enter the market, potentially disrupting traditional business models.</p><p>
<strong>Strategic Developments Reshaping Competition</strong></p><p>
</p><p>Recent years have witnessed several transformative developments:</p><p>
</p><p>
</p><p>These strategic shifts are redefining value creation in synthetic biology, with companies increasingly competing on platform robustness and data capabilities rather than individual product offerings. As the market matures, partnerships between biotech innovators and industrial end-users will likely become the primary growth driver rather than standalone technology sales.</p><p>
</p><p>
<strong>GLOBAL SYNTHETIC BIOLOGY MARKET TRENDS</strong></p><p>
<strong>Rising Demand for Biofuels and Sustainable Solutions Accelerates Market Growth</strong></p><p>
</p><p>The global synthetic biology market is experiencing accelerated growth due to increasing demand for <strong>biofuels and green alternatives</strong> across industries. With global biofuel production estimated at 170 billion liters in 2024 and projected to reach 250 billion liters by 2032, synthetic biology plays a pivotal role in engineering more efficient microbial strains for biofuel production. Furthermore, the market is witnessing breakthroughs in bio-based materials, where genetically modified organisms are being deployed to produce sustainable alternatives to plastics and chemicals. Companies are investing heavily in metabolic engineering and pathway optimization technologies to enhance yield and reduce production costs.</p><p>
<strong>Other Trends</strong></p><p>
</p><p><strong>Healthcare and Therapeutics Innovation</strong></p><p>
</p><p>The healthcare sector continues to dominate synthetic biology applications, with the market for synthetic biologic drugs projected to exceed $60 billion by 2032. Advancements in <strong>cell and gene therapies</strong> are driving this growth, particularly in oncology and rare disease treatment. Novel techniques like mRNA vaccine platforms, which demonstrated their potential during the COVID-19 pandemic, are being adapted for broader therapeutic applications. Additionally, synthetic biology enables the development of next-generation diagnostics, including CRISPR-based detection systems that offer faster and more accurate results.</p><p>
<strong>Automation and AI Integration Transform R&amp;D Processes</strong></p><p>
</p><p>The integration of <strong>AI and laboratory automation</strong> is revolutionizing synthetic biology research. Automated DNA synthesis platforms can now produce genetic constructs at unprecedented speeds, reducing development timelines by up to 70% compared to traditional methods. Machine learning algorithms are being employed to predict protein structures, optimize genetic circuits, and model complex biological systems. This technological convergence is enabling companies to scale their operations while maintaining precision, with some platforms capable of processing thousands of genetic variants simultaneously for industrial applications.</p><p>

</p><p><strong>"The research indicates that the synthetic biology market will grow from $12.4 billion in 2024 to $60.8 billion by 2032, with a CAGR of 21.9% during the forecast period."</strong></p><p>

<strong>Regional Analysis: Global Synthetic Biology Market</strong></p><p>
</p><p><strong>North America</strong></p><p>
North America dominates the synthetic biology market, with the United States accounting for over 40% of global revenue in 2024. The region benefits from substantial government funding, including the National Science Foundation's $3 billion investment in bioengineering research through 2025. Leading companies like Ginkgo Bioworks and Twist Bioscience drive innovation in gene synthesis and genome editing applications. While the medical sector remains the primary growth driver, increasing adoption in sustainable chemicals and materials demonstrates the technology's versatility. Regulatory clarity from the FDA on engineered organisms provides a stable framework, though ethical concerns about genetic manipulation continue to spark debate.</p><p>
</p><p><strong>Europe</strong></p><p>
Europe maintains a strong position with a focus on ethical biomanufacturing and circular economy applications. The EU's Horizon Europe program has allocated â¬1.2 billion for synthetic biology projects through 2027, targeting climate change mitigation and healthcare solutions. Strict GMO regulations under Directive 2001/18/EC create compliance challenges but also drive precision in genetic engineering techniques. Germany and the UK lead in industrial biotechnology applications, with BASF and Novozymes expanding production of bio-based chemicals. The region shows particular strength in enzyme engineering for waste valorization, aligning with its ambitious sustainability goals.</p><p>
</p><p><strong>Asia-Pacific</strong></p><p>
As the fastest-growing regional market, Asia-Pacific is projected to achieve a 31% CAGR through 2032. China's Made in China 2025 initiative prioritizes synthetic biology development, with support for over 50 industrial biotech parks. India emerges as a cost-effective research hub, while Japan dominates in precision fermentation technologies. The region sees explosive demand for synthetic biology in agriculture, including drought-resistant crops and alternative proteins. However, intellectual property protection remains inconsistent across markets, creating challenges for technology transfer. Emerging production hubs in Singapore and South Korea balance innovation with regulatory oversight.</p><p>
</p><p><strong>South America</strong></p><p>
South America shows promising but uneven growth, with Brazil representing nearly 60% of regional market value. The region leverages natural biodiversity for bio-prospecting while developing local synthetic biology capabilities. Agricultural applications dominate, particularly in sugarcane-derived biofuels and crop enhancement. Argentina's regulatory framework for genetically modified organisms remains among the region's most progressive. However, economic instability and limited research funding hinder broader adoption. Recent partnerships with European and North American firms signal growing recognition of the region's potential in sustainable biomaterials production.</p><p>
</p><p><strong>Middle East &amp; Africa</strong></p><p>
This emerging market focuses on healthcare solutions and alternative food production to address regional challenges. The UAE leads in synthetic biology adoption through initiatives like Dubai's Synthetic Biology Strategy 2030. South Africa shows strength in biomedical applications, including synthetic vaccines. While funding constraints limit large-scale R&amp;D, regional governments increasingly recognize synthetic biology's potential for economic diversification beyond oil. Saudi Arabia's NEOM project includes dedicated biotechnology zones, indicating long-term commitment. Infrastructure gaps and talent shortages remain significant barriers to growth across most African markets.</p><p>
</p><p></p><p><strong>Key Report Takeaways</strong></p><p></p><p>
</p><p>
</p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p></p><p>

</p><p>
<strong>Report Scope</strong></p><p>
</p><p>This report presents a comprehensive analysis of the global and regional markets for Synthetic Biology, covering the period from 2024 to 2032. It includes detailed insights into the current market status and outlook across various regions and countries, with specific focus on:</p><p>
</p><p><strong>Sales, sales volume, and revenue forecasts</strong></p><p><strong>Detailed segmentation by type and application</strong></p><p>
</p><p>In addition, the report offers in-depth profiles of key industry players, including:</p><p>
</p><p>Company profiles</p><p>Product specifications</p><p>Production capacity and sales</p><p>Revenue, pricing, gross margins</p><p>Sales performance</p><p>
</p><p>It further examines the competitive landscape, highlighting the major vendors and identifying the critical factors expected to challenge market growth.</p><p>
</p><p>As part of this research, we surveyed Synthetic Biology companies and industry experts. The survey covered various aspects, including:</p><p>
</p><p>Revenue and demand trends</p><p>Product types and recent developments</p><p>Strategic plans and market drivers</p><p>Industry challenges, obstacles, and potential risks</p><p>
<strong>FREQUENTLY ASKED QUESTIONS:</strong></p><p>
<strong>What is the current market size of Global Synthetic Biology Market?</strong></p><p>
</p><p><strong>-&gt;</strong> Global synthetic biology market was valued at <strong>USD 13.4 billion in 2024</strong> and is projected to reach <strong>USD 45.8 billion by 2032</strong>, growing at a <strong>CAGR of 23.5%</strong>.</p><p>
<strong>Which key companies operate in Global Synthetic Biology Market?</strong></p><p>
</p><p><strong>-&gt; Key players</strong> include <strong>Thermo Fisher, Ginkgo Bioworks, Novozymes, Merck KGaA, Amyris, Agilent, Twist Bioscience</strong>, and <strong>Synthetic Genomics</strong>, among others.</p><p>
<strong>What are the key growth drivers?</strong></p><p>
</p><p>-&gt; Key growth drivers include <strong>rising demand for synthetic genes, advancements in CRISPR technology, increasing R&amp;D investments, and growing applications in pharmaceuticals and industrial biotechnology</strong>.</p><p>
<strong>Which region dominates the market?</strong></p><p>
</p><p><strong>-&gt; North America</strong> currently holds the largest market share, while <strong>Asia-Pacific</strong> is emerging as the fastest-growing region due to government initiatives and increasing biotech investments.</p><p>
<strong>What are the emerging trends?</strong></p><p>
</p><p>-&gt; Emerging trends include <strong>automation in DNA synthesis, AI-driven bioengineering, bio-based materials production, and expansion of cell-free synthetic biology systems</strong>.</p><p>
</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/100708/global-synthetic-biology-market">
            https://www.24chemicalresearch.com/reports/100708/global-synthetic-biology-market</a></b></div><br>
            <b>Table of Content:</b><p>Chapter 1 Industry Overview<br />
<br>1.1 Definition<br />
<br>1.2 Assumptions<br />
<br>1.3 Research Scope<br />
<br>1.4 Market Analysis by Regions<br />
<br>1.4.1 North America Market States and Outlook (2022-2027)<br />
<br>1.4.2 East Asia Market States and Outlook (2022-2027)<br />
<br>1.4.3 Europe Market States and Outlook (2022-2027)<br />
<br>1.4.4 South Asia Market States and Outlook (2022-2027)<br />
<br>1.4.5 Southeast Asia Market States and Outlook (2022-2027)<br />
<br>1.4.6 Middle East Market States and Outlook (2022-2027)<br />
<br>1.4.7 Africa Market States and Outlook (2022-2027)<br />
<br>1.4.8 Oceania Market States and Outlook (2022-2027)<br />
<br>1.4.9 South America Market States and Outlook (2022-2027)<br />
<br>1.5 Global Synthetic Biology Market Size Analysis from 2022 to 2027<br />
<br>1.5.1 Global Synthetic Biology Market Size Analysis from 2022 to 2027 by Consumption Volume<br />
<br>1.5.2 Global Synthetic Biology Market Size Analysis from 2022 to 2027 by Value<br />
<br>1.5.3 Global Synthetic Biology Price Trends Analysis from 2022 to 2027<br />
<br>1.6 COVID-19 Outbreak: Synthetic Biology Industry Impact<br />
<br>Chapter 2 Global Synthetic Biology Competition by Types, Applications, and Top Regions and Countries<br />
<br>2.1 Global Synthetic Biology (Volume and Value) by Type<br />
<br>2.1.1 Global Synthetic Biology Consumption and Market Share by Type (2016-2021)<br />
<br>2.1.2 Global Synthetic Biology Revenue and Market Share by Type (2016-2021)<br />
<br>2.2 Global Synthetic Biology (Volume and Value) by Application<br />
<br>2.2.1 Global Synthetic Biology Consumption and Market Shar</p>

<div><b>Get the Complete Report & TOC @ 
            <a href="https://www.24chemicalresearch.com/reports/100708/global-synthetic-biology-market">
            https://www.24chemicalresearch.com/reports/100708/global-synthetic-biology-market</a></b></div><br>

<b>CONTACT US:</b><br>
            203A, City Vista, Fountain Road, Kharadi, Pune, India - 411014<br>
            International: +1(332) 2424 294<br>
            Asia: +91 9169162030 <br><br>
            Follow Us On LinkedIn: <a href="https://www.linkedin.com/company/24chemicalresearch/">24ChemicalResearch LinkedIn</a>